Muralidhar Krishnaiah, MD
Neurology with Special Qualifications in Child Neurology · Toms River, NJNPI 1427071729
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $748, 2.5 times the $296 reported in 2019.
Across 126 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$493
- Johnson & Johnson$408
- Sunovion Pharmaceuticals Inc.$273
- Alkermes, Inc.$225
- Neurocrine Biosciences, Inc.$165
- AbbVie$144
- plus $524 from 7 others
What the payments were for
- Food & beverage$2,11995%
- Education$1115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $493 |
| Johnson & Johnson | 23 | $408 |
| Sunovion Pharmaceuticals Inc. | 16 | $273 |
| Alkermes, Inc. | 13 | $225 |
| Neurocrine Biosciences, Inc. | 10 | $165 |
| AbbVie(2 entities) | 9 | $144 |
| Otsuka America Pharmaceutical, Inc. | 7 | $131 |
| Indivior Inc. | 8 | $128 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $106 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| Braeburn Inc. | 3 | $47 |
| Bioxcel Therapeutics, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $15 |
How this compares
$2,230 in reported general payments places this provider in the 80th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.
See all neurology with special qualifications in child neurology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 58 | $196,264 |
| Abilify MaintenaAripiprazole | 27 | $121,663 |
| AplenzinBupropion Hbr | 12 | $72,545 |
| AristadaAripiprazole Lauroxil | 16 | $63,246 |
| CaplytaLumateperone Tosylate | 19 | $58,439 |
| VivitrolNaltrexone Microspheres | 28 | $44,854 |
| VraylarCariprazine Hcl | 29 | $40,880 |
| Risperidone | 40 | $667 |
| Olanzapine | 18 | $530 |
| Mirtazapine | 18 | $493 |
| Divalproex Sodium | 14 | $398 |
| Topiramate | 20 | $362 |
| Propranolol Hcl | 15 | $218 |
| Hydroxyzine Hcl | 12 | $201 |
| Gabapentin | 13 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $408 | $196,26458 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $131 | $121,66327 claims |
| Alkermes, Inc.Aristada, Vivitrol | $225 | $108,10044 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $106 | $58,43919 claims |
| AbbVieVraylar | $144 | $40,88029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.
Other neurology with special qualifications in child neurology in Toms River
- Juliann PaolicchiHackensack$80K
- Trevor DesouzaMorristown$14K
- Rao PasupuletiHamilton$11K
- Aliza AlterLivingston$9K
- Sara RubensteinHackensack$7K
- Carlos LastraNew Brunswick$5K
- Jacqueline RomeroMarlboro$4K
- Sohum TrivediMarlboro$4K
- Romana KulikovaGarwood$4K
- Rajeshwari MahalinghamNew Brunswick$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.